Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Phase Ib Clinical Trial Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Nelmastobart in Combination With TAS-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer

NCT07656038 is registered in ClinicalTrials.gov with STCube, Inc. as lead sponsor.

NCT NCT07656038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07656038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Phase Ib Clinical Trial Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Nelmastobart in Combination With TAS-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer
Lead sponsor
STCube, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
July 31, 2028
Enrollment
45 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colonrectal cancer (crc)